Anemia Aplastik

01Pathophysiology

Aplastic anemia is fundamentally a disease of bone marrow failure. The central event is destruction or suppression of multipotent hematopoietic stem cells, leading to inadequate production of all three blood cell lineages: red blood cells, white blood cells, and platelets. This results in the hallmark finding of pancytopenia.

In the acquired form, which accounts for the majority of cases, the mechanism is autoimmune. Oligoclonal expansion of cytotoxic CD8+ T lymphocytes targets and destroys hematopoietic stem and progenitor cells. These T cells release interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha), which upregulate the Fas receptor on stem cells, triggering apoptosis. This autoimmune attack is why immunosuppressive therapy is effective in patients who are not transplant candidates.

The connection between pathophysiology and presentation is straightforward. Because the stem cell compartment is destroyed, the marrow cannot replenish mature blood cells. Anemia explains the fatigue, pallor, and exertional dyspnea. Neutropenia explains the recurrent infections and fevers. Thrombocytopenia explains the bleeding diathesis, including petechiae, mucosal bleeding, and easy bruising. Importantly, the reticulocyte count is low, because the marrow simply cannot mount a response. This distinguishes aplastic anemia from peripheral destruction processes (like autoimmune hemolytic anemia) where the reticulocyte count would be elevated.

In drug-induced cases, the offending agent either directly damages stem cells (dose-dependent toxicity, as with benzene or radiation) or triggers an idiosyncratic immune-mediated reaction (as classically seen with chloramphenicol). Post-hepatitis aplastic anemia typically follows a seronegative (non-A, non-B, non-C) hepatitis episode by 2 to 3 months, and it carries a severe prognosis.

The inherited forms (Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome) involve germline mutations affecting DNA repair or telomere maintenance. These patients present earlier in life and often have associated physical anomalies such as short stature, cafe-au-lait spots, thumb or radial ray abnormalities (Fanconi anemia), or abnormal skin pigmentation and nail dystrophy (dyskeratosis congenita).

02Classification and Clinical Manifestation

Severity Classification (Modified Camitta Criteria)

This classification directly determines treatment decisions and is highly testable.

Clinical Manifestation by Lineage

Inherited vs. Acquired

03Diagnostic Workup

The diagnostic journey begins when a patient presents with symptoms referable to more than one blood cell lineage. The best initial test is a complete blood count (CBC) with differential and a reticulocyte count. The hallmark finding is pancytopenia with a low reticulocyte count. This combination is critical: it tells you the problem is underproduction, not destruction.

Once pancytopenia with reticulocytopenia is identified, the next step is a peripheral blood smear. In aplastic anemia, the RBCs appear normal in size and color (normocytic, normochromic). There are no blasts (which would suggest leukemia), no teardrop cells (which would suggest myelofibrosis), and no hypersegmented neutrophils (which would suggest megaloblastic anemia). The smear is "boring" except for the reduced cell counts.

The most accurate (confirmatory) test is the bone marrow biopsy. This is non-negotiable for diagnosis. A biopsy, not just an aspirate, is required because you need to assess overall cellularity and architecture. The classic finding is a markedly hypocellular marrow where hematopoietic tissue has been replaced by fat cells. The few remaining hematopoietic cells are morphologically normal (no dysplasia). If the aspirate yields a "dry tap" (no marrow is obtained), this itself is suggestive of either aplastic anemia or myelofibrosis, and a biopsy becomes even more essential.

Once the diagnosis is established, additional workup serves to classify severity, identify etiology, and screen for associated conditions. Flow cytometry for PNH is standard because aplastic anemia and PNH share a pathophysiologic link; small PNH clones are found in up to 50% of patients. Cytogenetic analysis helps exclude MDS, which can mimic aplastic anemia but shows clonal chromosomal abnormalities and dysplastic morphology. Chromosomal breakage testing with diepoxybutane (DEB) or mitomycin C (MMC) should be performed in all young patients to rule out Fanconi anemia, because the treatment approach differs substantially (Fanconi patients require modified transplant conditioning regimens).

04Management and Treatment

Acute stabilization is the first priority. Patients presenting with severe neutropenia and fever require immediate broad-spectrum antibiotics (treat as febrile neutropenia). Active bleeding from thrombocytopenia requires platelet transfusion. Packed red blood cell transfusion is given for symptomatic anemia.

A critical principle for transplant candidates is to minimize blood product exposure to reduce the risk of alloimmunization and graft rejection. All blood products should be irradiated (to prevent transfusion-associated graft-versus-host disease) and leukoreduced. Family members should never serve as blood donors if there is any possibility they may later be stem cell donors.

For definitive treatment, the decision tree hinges on patient age and donor availability:

Allogeneic HSCT is the treatment of choice for patients under 40 years who have an HLA-matched sibling donor. The standard conditioning regimen uses high-dose cyclophosphamide (200 mg/kg total, given as 50 mg/kg/day for 4 days) combined with ATG. This approach yields long-term survival rates of 75-90%. For older patients or those receiving grafts from unrelated donors, reduced-intensity conditioning is used to lower toxicity.

Immunosuppressive therapy is the standard treatment when transplant is not feasible. The combination of horse ATG (Atgam, 40 mg/kg/day intravenously for 4 consecutive days) and cyclosporine (5-6 mg/kg/day orally, divided into two doses, continued for at least 12-24 months with slow taper) achieves hematologic response in approximately 60-70% of patients. Horse ATG is preferred over rabbit ATG for initial therapy based on superior response rates demonstrated in clinical trials. Methylprednisolone is given during ATG infusion to mitigate serum sickness. Eltrombopag (thrombopoietin receptor agonist, 150 mg/day orally) is increasingly added to first-line IST based on data showing improved complete response rates.

Cyclosporine levels must be monitored (target trough 200-400 ng/mL) given the drug's nephrotoxicity and narrow therapeutic window. Response to IST takes time, and most patients show improvement by 3 to 6 months.

Long-term management includes monitoring for clonal evolution. Approximately 10-15% of patients treated with IST may develop MDS, AML, or PNH over the following decade. Regular CBCs, periodic PNH flow cytometry screening, and bone marrow surveillance are indicated.

Patients with non-severe disease who are transfusion-independent may be observed closely. If counts decline or transfusion requirements develop, cyclosporine monotherapy or combined IST is initiated.

Contraindications and cautions: Horse ATG requires a skin test before administration due to the risk of anaphylaxis. Cyclosporine must be used cautiously in renal impairment. Androgens (danazol) may be considered as adjunctive therapy but are not first-line. Growth factors (G-CSF) have limited and controversial benefit and are not standard monotherapy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get aplastic anemia questions wrong is by confusing it with MDS. Both cause pancytopenia. Both can present in older adults. Hypocellular MDS even mimics the marrow appearance. The discriminator is always morphology and cytogenetics: MDS has dysplastic changes and often clonal abnormalities, while aplastic anemia has a hypocellular but morphologically normal marrow with a normal karyotype. If a vignette describes pancytopenia with a hypocellular marrow but also mentions ring sideroblasts, bilobed neutrophils, or monosomy 7, that is MDS, not aplastic anemia.

A second common trap is the reticulocyte count. Students see anemia and assume the marrow should be trying to compensate. In aplastic anemia, the reticulocyte count is low because the stem cell compartment is destroyed. A high reticulocyte count with pancytopenia points you toward a peripheral destruction process (such as hypersplenism, autoimmune cytopenias, or PNH with hemolysis), not aplastic anemia.

The third trap involves splenomegaly. Aplastic anemia does not cause splenomegaly. If a vignette describes pancytopenia with an enlarged spleen, you must think of myelofibrosis, hairy cell leukemia, lymphoma, or hypersplenism. The absence of splenomegaly in a pancytopenic patient is actually a clue pointing toward aplastic anemia.

Students also struggle with the treatment algorithm. The decision between transplant and immunosuppression is determined by age and donor availability. A young patient with a matched sibling donor gets transplant. An older patient or one without a donor gets ATG plus cyclosporine. A common distractor is offering cyclosporine alone to a young patient with an available donor, or offering transplant to an elderly patient without discussion of fitness and conditioning modifications.

Finally, never forget the drug history. Chloramphenicol is the classic drug association on exams, but carbamazepine, sulfonamides, phenytoin, and NSAIDs also appear. A vignette that provides a medication list is deliberately testing whether you can link the drug to the marrow failure. Similarly, a history of hepatitis 2 to 3 months before the onset of pancytopenia (especially when all hepatitis serologies are negative) is a well-known setup for post-hepatitis aplastic anemia.

The core competency being tested with aplastic anemia is your ability to recognize a hypoproductive pancytopenia (low reticulocytes, empty marrow, no splenomegaly, no blasts) and to correctly sequence the diagnostic workup from CBC to marrow biopsy, while distinguishing it from the many conditions that mimic it.